Evidence map›Paper›PMID 42635463›Full record

ArticleJournal of viral hepatitis2026

Virologic Response to Antiviral Therapy in Chronic Hepatitis B Patients With High Viral Load: A Real-World Cohort Study.

Siwei Zheng, Xueyan Li, Hongli Liu, Tianhao Mao, You Ge, Wenjing Ji, Xixuan Wang, Yijun Bao, Yu Zhang, Anling Zhou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Siwei ZhengDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University, Nanjing, China.
Xueyan LiDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University, Nanjing, China.
Hongli LiuDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-6633-6795
Tianhao MaoDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0009-0007-2957-500X
You GeDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0003-4497-7916
Wenjing JiDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Xixuan WangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Teaching Hospital of Southeast University, Nanjing, China.
Yijun BaoDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0002-1575-1574
Yu ZhangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0009-0009-1844-0892
Anling ZhouDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, The Affiliated Nanjing No. 2 Clinical College of Xuzhou Medical University, Nanjing, China.
Qunzeng DanzengDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Teaching Hospital of Southeast University, Nanjing, China.
Jialuo WangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Feng YangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Teaching Hospital, Nanjing Medical University School of Public Health, Nanjing, China.
Qingfang XiongDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.ORCID https://orcid.org/0000-0001-6746-9389
Yongfeng YangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Clinical Teaching Hospital of Medical School, Nanjing University, Nanjing, China.ORCID https://orcid.org/0000-0002-3214-0038

Funding

Natural Science Foundation of Jiangsu Province BK20251727
6 · The paper itself

Abstract

Current guidelines for chronic hepatitis B (CHB) have progressively expanded antiviral treatment indications, with age > 30 years increasingly being incorporated as an important criterion. However, real-world evidence regarding treatment outcomes in this expanded population remains limited. This study evaluated the 48-week treatment response and its independent predictors in treatment-naïve CHB patients aged > 30 years with a high baseline viral load. This retrospective study included 808 treatment-naïve CHB patients aged > 30 years with baseline HBV DNA ≥ 2000 IU/mL who received first-line nucleos(t)ide analogue (NA) monotherapy. Patients were classified into moderately high (MH; ≥ 2 × 10

Indexed as

Antiviral AgentsHepatitis B, ChronicSustained Virologic ResponseViral LoadAdultAgedDNA, ViralFemaleHepatitis B e AntigensHepatitis B virusHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntiviral AgentsDNA, ViralHepatitis B e Antigensageantiviral therapychronic hepatitis Bguidelinereal‐world studyvirological response

Identifiers

PMID42635463
PMCPMC13502117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.